Archives of Medical Research
Volume 37, Issue 7 , Pages 895-898 , October 2006

Seroprevalence of Hepatitis B and Hepatitis C in Patients with Thalassemia and Sickle Cell Anemia in a Long-term Follow-up

  • Sabahattin Ocak

      Affiliations

    • Department of Infectious Disease and Clinical Microbiology, Mustafa Kemal Univerisity, Hatay, Turkey
    • Corresponding Author InformationAddress reprint requests to: Assistant Professor Dr. Sabahattin Ocak, Mustafa Kemal Üniversitesi, Tıp Fakültesi, Dekanlıgı, Hatay, Turkey
    • ,
  • Hasan Kaya

      Affiliations

    • Department of Internal Medicine, Mustafa Kemal Univerisity, Hatay, Turkey
    • ,
  • Meryem Cetin

      Affiliations

    • Department of Microbiology and Clinical Microbiology, Medical Faculty, Mustafa Kemal Univerisity, Hatay, Turkey
    • ,
  • Edip Gali

      Affiliations

    • Hemoglobinopathy Center of Antakya State Hospital, Hatay, Turkey
    • ,
  • Muge Ozturk

      Affiliations

    • Hemoglobinopathy Center of İskenderun State Hospital, Hatay, Turkey

Received 12 September 2005 ,Accepted 10 April 2006.

References 

  1. Canatan D, Oguz N, Güvendik I. The incidence of alfa-thalassemia in Antalya-Turkey. Turk J Haematol. 2002;19:433–434
  2. Tadmouri GO, Yüksel L, Başak AN. HbS/beta(del)-thalassemia associated with high levels of hemoglobins A2 and F in a Turkish family. Am J Hematol. 1998;59:83–86
  3. Kebudi R, Ayan I, Yılmaz G, Akici F, Görgün Ö, Badur S. Seroprevalence of hepatitis B, hepatitis C, and human immunodeficiency virus infections in children with cancer at diagnosis and following therapy in Turkey. Med Pediatr Oncol. 2000;34:102–105
  4. Mollah AH, Nahar N, Siddique MA, Anwar KS, Hassan T, Azam MG. Common transfusion-transmitted infectious agents among thalassaemic children in Bangladesh. J Health Popul Nutr. 2003;21:67–71
  5. Wanachiwanawin W, Luengrojanakul P, Sirangkapracha P, Leowattana W, Fucharoen S. Prevalence and clinical significance of hepatitis C virus infection in Thai patients with thalassemia. Int J Hematol. 2003;78:374–378
  6. Christofidou M, Lambropoulou-Karatza C, Dimitracopoulos G, Spiliopoulou I. Distribution of hepatitis C virus genotypes in viremic patients with beta-thalassemia. Eur J Clin Microbiol Infect Dis. 2000;19:728–730
  7. Al-Sheyyab M, Batieha B, El-Khateeb M. The prevalence of hepatitis B, hepatitis C and human immunodeficiency virus markers in multi-transfused patients. J Trop Pediatr. 2001;47:239–242
  8. Yen-Hsuan NI, Mei-Hwei C, Kai-Hsin L, Pei-Jer C, Dong-Tsamn L, Hong-Yuan H, et al. Hepatitis C virus in thalassemic children: clinical and molecular studies. Pediatr Res. 1996;39:323–328
  9. Tawk HM, Vickery K, Bisset L, Lo SK, Cossart YE. The significance of transfusion in the past as a risk for current hepatitis B and hepatitis C infection: a study in endoscopy patients. Transfusion. 2005;45:807–813
  10. Karimi M, Ghavanini AA. Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus antibodies among multitransfused thalassaemic children in Shiraz, Iran. J Paediatr Child Health. 2001;37:564–566
  11. Mıstık R, Balık İ. Epidemiologic analysis of viral hepatitis in Turkey. Viral Hepatit. 2003;1:9–55
  12. Temiz T, Nergiz Ş, Özbek E. The evaluation of HbsAg, anti-HCV, Anti-HIV and syphilis in blood donors who applied to Dicle University Medical Faculty Blood Bank. Viral Hepatit Dergisi. 2004;9:166–169
  13. Ocak S, Duran N, Savaş L, Önlen Y, Ediboğlu MA. HBV, HCV, HIV and VDRL seropositivity in blood donors in Hatay. Viral Hepatit Dergisi. 2005;10:49–53
  14. Wanachiwanawin W. Infections in E-beta thalassemia. J Pediatr Hematol Oncol. 2000;22:581–587
  15. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin is frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol. 2002;117:755–758
  16. Ramia S, Koussa S, Taher A, Haraki S, Klayme S, Sarkis D, et al. Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassemics. Ann Trop Med Parasitol. 2002;96:197–202
  17. Ardalan FA, Osquei MR, Toosi MN, Irvanloo G. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study. BMC Gastroenterol. 2004;4:17
  18. Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ, et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and implementing for future HBV NAT. Transfusion. 2002;42:1365–1372
  19. Badur S. Viral hepatitis in Turkey. Status report of the Turkish Society for prevention of viral hepatitis (in Turkish). In:  Kiliçturgay K editors. Viral Hepatitis 94. İstanbul: Nobel Tip Publisher; 1994;p. 15–38
  20. Çetingül N, Kavaklı K, Vergin C. Hepatitis-B, hepatitis-C, CMV and HIV markers in pediatric malignancies. Turkish J Cancer. 1994;24:75–80
  21. Chung JL, Kao JH, Kong MS, Yang CP, Hung IJ, Lin TY. Hepatitis C and G virus infections in polytransfused children. Eur J Pediatr. 1997;56:546–549
  22. McCullough J. Transfusion medicine: discipline with a future. Transfusion. 2003;43:823–828
  23. al-Mahroos FT, Ebrahim A. Prevalence of hepatitis B, hepatitis C and human immune deficiency virus markers among patients with hereditary haemolytic anaemias. Ann Trop Paediatr. 1995;15:121–128
  24. Hasan MF, Marsh F, Posner G, Bellevue R, Dosik H, Suatengco R, et al. Chronic hepatitis C in patients with sickle cell disease. Am J Gastroenterol. 1996;91:1204–1206

PII: S0188-4409(06)00162-7

doi: 10.1016/j.arcmed.2006.04.007

Archives of Medical Research
Volume 37, Issue 7 , Pages 895-898 , October 2006

Article Tools